1887

Abstract

Japanese encephalitis remains the leading cause of viral encephalitis in children in Asia and is expanding its geographical range to larger areas in Asia and Australasia. Five genotypes of Japanese encephalitis virus (JEV) co-circulate in the geographically affected areas. In particular, the emergence of genotype I (GI) JEV has displaced genotype III (GIII) as the dominant circulating genotype in many Asian regions. However, all approved vaccine products are derived from GIII strains. In the present study, bioinformatic analysis revealed that GI and GIII JEV strains shared two distinct amino acid residues within the envelope (E) protein (E222 and E327). By using reverse genetics approaches, A222S and S327T mutations were demonstrated to decrease live-attenuated vaccine (LAV) SA14-14-2-induced neutralizing antibodies in humans, without altering viral replication. A222S or S327T mutations were then rationally engineered into the infectious clone of SA14-14-2, and the resulting mutant strains retained the same genetic stability and attenuation characteristics as the parent strain. More importantly, immunization of mice with LAV-A222S or LAV-S327T elicited increased neutralizing antibodies against GI strains. Together, these results demonstrated that E222 and E327 are potential genotype-related neutralization determinants and are critical in determining the protective efficacy of live Japanese encephalitis vaccine SA14-14-2 against circulating GI strains. Our findings will aid in the rational design of the next generation of Japanese encephalitis LAVs capable of providing broad protection against all JEV strains belonging to different genotypes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000160
2015-08-01
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/8/2165.html?itemId=/content/journal/jgv/10.1099/vir.0.000160&mimeType=html&fmt=ahah

References

  1. Austin S.K., Dowd K.A., Shrestha B., Nelson C.A., Edeling M.A., Johnson S., Pierson T.C., Diamond M.S., Fremont D.H.. ( 2012;). Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8: e1002930 [CrossRef] [PubMed].
    [Google Scholar]
  2. Beasley D.W., Li L., Suderman M.T., Guirakhoo F., Trent D.W., Monath T.P., Shope R.E., Barrett A.D.. ( 2004;). Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22: 3722–3726 [CrossRef] [PubMed].
    [Google Scholar]
  3. Beasley D.W.C., Lewthwaite P., Solomon T.. ( 2008;). Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 8: 95–106 [CrossRef] [PubMed].
    [Google Scholar]
  4. Bernardo L., Fleitas O., Pavón A., Hermida L., Guillén G., Guzman M.G.. ( 2009;). Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 16: 1829–1831 [CrossRef] [PubMed].
    [Google Scholar]
  5. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., Ohrr H.C., Tang J.L., Halstead S.B.. ( 2001;). Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358: 791–795 [CrossRef] [PubMed].
    [Google Scholar]
  6. Bonaparte M., Dweik B., Feroldi E., Meric C., Bouckenooghe A., Hildreth S., Hu B., Yoksan S., Boaz M.. ( 2014;). Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis 14: 156 [CrossRef] [PubMed].
    [Google Scholar]
  7. Brien J.D., Austin S.K., Sukupolvi-Petty S., O'Brien K.M., Johnson S., Fremont D.H., Diamond M.S.. ( 2010;). Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84: 10630–10643 [CrossRef] [PubMed].
    [Google Scholar]
  8. Cecilia D., Gould E.A.. ( 1991;). Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181: 70–77 [CrossRef] [PubMed].
    [Google Scholar]
  9. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., White L.J., Diamond M.S., Baric R.S., other authors. ( 2012;). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109: 7439–7444 [CrossRef] [PubMed].
    [Google Scholar]
  10. Erra E.O., Askling H.H., Yoksan S., Rombo L., Riutta J., Vene S., Lindquist L., Vapalahti O., Kantele A.. ( 2013;). Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 56: 267–270 [CrossRef] [PubMed].
    [Google Scholar]
  11. Fan Y.C., Chen J.M., Chiu H.C., Chen Y.Y., Lin J.W., Shih C.C., Chen C.M., Chang C.C., Chang G.J., Chiou S.S.. ( 2012;). Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis 6: e1834 [CrossRef] [PubMed].
    [Google Scholar]
  12. Ferguson M., Johnes S., Li L., Heath A., Barrett A.. ( 2008;). Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines – report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 36: 111–116 [CrossRef] [PubMed].
    [Google Scholar]
  13. Feroldi E., Pancharoen C., Kosalaraksa P., Chokephaibulkit K., Boaz M., Meric C., Hutagalung Y., Bouckenooghe A.. ( 2014;). Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J 33: 643–649 [CrossRef] [PubMed].
    [Google Scholar]
  14. Gatchalian S., Yao Y., Zhou B., Zhang L., Yoksan S., Kelly K., Neuzil K.M., Yaïch M., Jacobson J.. ( 2008;). Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 26: 2234–2241 [CrossRef] [PubMed].
    [Google Scholar]
  15. Goncalvez A.P., Chien C.H., Tubthong K., Gorshkova I., Roll C., Donau O., Schuck P., Yoksan S., Wang S.D., other authors. ( 2008;). Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro in vivo. J Virol 82: 7009–7021 [CrossRef] [PubMed].
    [Google Scholar]
  16. Gromowski G.D., Barrett A.D.. ( 2007;). Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349–360 [CrossRef] [PubMed].
    [Google Scholar]
  17. Gromowski G.D., Firestone C.Y., Hanson C.T., Whitehead S.S.. ( 2014;). Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine 32: 3010–3018 [CrossRef] [PubMed].
    [Google Scholar]
  18. Halstead S.B., Thomas S.J.. ( 2010;). Japanese encephalitis: new options for active immunization. Clin Infect Dis 50: 1155–1164 [CrossRef] [PubMed].
    [Google Scholar]
  19. Han N., Adams J., Chen P., Guo Z.Y., Zhong X.F., Fang W., Li N., Wen L., Tao X.Y., other authors. ( 2014;). Comparison of genotypes I and III in Japanese encephalitis virus reveal distinct differences in their genetic and host diversity. J Virol 88: 11469–11479 [CrossRef].
    [Google Scholar]
  20. Hanna J.N., Ritchie S.A., Phillips D.A., Shield J., Bailey M.C., Mackenzie J.S., Poidinger M., McCall B.J., Mills P.J.. ( 1996;). An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust 165: 256–260 [PubMed].
    [Google Scholar]
  21. Hasegawa H., Yoshida M., Fujita S., Kobayashi Y.. ( 1994;). Comparison of structural proteins among antigenically different Japanese encephalitis virus strains. Vaccine 12: 841–844 [CrossRef] [PubMed].
    [Google Scholar]
  22. Hasegawa H., Yoshida M., Kobayashi Y., Fujita S.. ( 1995;). Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies. Vaccine 13: 1713–1721 [CrossRef] [PubMed].
    [Google Scholar]
  23. Hennessy S., Strom B.L., Bilker W.B., Zhengle L., Chao-Min W., Hui-Lian L., Tai-Xiang W., Hong-Ji Y., Qi-Mau L., other authors. ( 1996;). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347: 1583–1586 [CrossRef] [PubMed].
    [Google Scholar]
  24. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D.. ( 2005;). Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23: 5205–5211 [CrossRef] [PubMed].
    [Google Scholar]
  25. Hu Q., Chen B., Zhu Z., Tian J., Zhou Y., Zhang X., Zheng X.. ( 2013;). Recurrence of Japanese encephalitis epidemic in Wuhan, China, 2009–2010. PLoS One 8: e52687 [CrossRef] [PubMed].
    [Google Scholar]
  26. Kimura-Kuroda J., Yasui K.. ( 1983;). Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese encephalitis virus, using monoclonal antibodies. J Virol 45: 124–132 [PubMed].
    [Google Scholar]
  27. Kobayashi Y., Hasegawa H., Yamauchi T.. ( 1985;). Studies on the antigenic structure of Japanese encephalitis virus using monoclonal antibodies. Microbiol Immunol 29: 1069–1082 [CrossRef] [PubMed].
    [Google Scholar]
  28. Kochel T.J., Watts D.M., Halstead S.B., Hayes C.G., Espinoza A., Felices V., Caceda R., Bautista C.T., Montoya Y., other authors. ( 2002;). Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360: 310–312 [CrossRef] [PubMed].
    [Google Scholar]
  29. Kumar R., Tripathi P., Rizvi A.. ( 2009;). Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360: 1465–1466 [CrossRef] [PubMed].
    [Google Scholar]
  30. Kurane I., Takasaki T.. ( 2000;). Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18: (Suppl 2), 33–35 [CrossRef] [PubMed].
    [Google Scholar]
  31. Li S.H., Dong H., Li X.F., Xie X., Zhao H., Deng Y.Q., Wang X.Y., Ye Q., Zhu S.Y., other authors. ( 2013a;). Rational design of a flavivirus vaccine by abolishing viral RNA 2′-O methylation. J Virol 87: 5812–5819 [CrossRef] [PubMed].
    [Google Scholar]
  32. Li X.F., Deng Y.Q., Yang H.Q., Zhao H., Jiang T., Yu X.D., Li S.H., Ye Q., Zhu S.Y., other authors. ( 2013b;). A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 87: 13694–13705 [CrossRef] [PubMed].
    [Google Scholar]
  33. Lin C.W., Wu S.C.. ( 2003;). A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol 77: 2600–2606 [CrossRef] [PubMed].
    [Google Scholar]
  34. Liu Z.L., Hennessy S., Strom B.L., Tsai T.F., Wan C.M., Tang S.C., Xiang C.F., Bilker W.B., Pan X.P., other authors. ( 1997;). Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 176: 1366–1369 [CrossRef] [PubMed].
    [Google Scholar]
  35. Liu X., Yu Y., Li M., Liang G., Wang H., Jia L., Dong G.. ( 2011;). Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine 29: 2127–2130 [CrossRef] [PubMed].
    [Google Scholar]
  36. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., other authors. ( 2008;). Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312–317 [CrossRef] [PubMed].
    [Google Scholar]
  37. Luca V.C., AbiMansour J., Nelson C.A., Fremont D.H.. ( 2012;). Crystal structure of the Japanese encephalitis virus envelope protein. J Virol 86: 2337–2346 [CrossRef] [PubMed].
    [Google Scholar]
  38. Ma S.P., Yoshida Y., Makino Y., Tadano M., Ono T., Ogawa M.. ( 2003;). Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 69: 151–154 [PubMed].
    [Google Scholar]
  39. Mackenzie J.S., Gubler D.J., Petersen L.R.. ( 2004;). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: (Suppl.), S98–S109 [CrossRef] [PubMed].
    [Google Scholar]
  40. Monath T.P., Seligman S.J., Robertson J.S., Guy B., Hayes E.B., Condit R.C., Excler J.L., Mac L.M., Carbery B., Chen R.T., Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). ( 2015;). Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33: 62–72 [CrossRef] [PubMed].
    [Google Scholar]
  41. Nga P.T., del Carmen Parquet M., Cuong V.D., Ma S.P., Hasebe F., Inoue S., Makino Y., Takagi M., Nam V.S., Morita K.. ( 2004;). Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J Gen Virol 85: 1625–1631 [CrossRef] [PubMed].
    [Google Scholar]
  42. Nitatpattana N., Dubot-Pérès A., Gouilh M.A., Souris M., Barbazan P., Yoksan S., de Lamballerie X., Gonzalez J.P.. ( 2008;). Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis 14: 1762–1765 [CrossRef] [PubMed].
    [Google Scholar]
  43. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., other authors. ( 2005;). Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522–530 [CrossRef] [PubMed].
    [Google Scholar]
  44. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.E., Olshevsky U., other authors. ( 2006;). Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149–12159 [CrossRef] [PubMed].
    [Google Scholar]
  45. Pan X.L., Liu H., Wang H.Y., Fu S.H., Liu H.Z., Zhang H.L., Li M.H., Gao X.Y., Wang J.L., other authors. ( 2011;). Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol 85: 9847–9853 [CrossRef] [PubMed].
    [Google Scholar]
  46. Parida M., Dash P.K., Tripathi N.K., Ambuj Sannarangaiah,S., Saxena P., Agarwal S., Sahni A.K., Singh S.P., other authors. ( 2006;). Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 12: 1427–1430 [CrossRef] [PubMed].
    [Google Scholar]
  47. Pitcher T.J., Gromowski G.D., Beasley D.W., Barrett A.D.. ( 2012;). Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology 422: 386–392 [CrossRef] [PubMed].
    [Google Scholar]
  48. Sarkar A., Taraphdar D., Mukhopadhyay S.K., Chakrabarti S., Chatterjee S.. ( 2012;). Molecular evidence for the occurrence of Japanese encephalitis virus genotype I and III infection associated with acute encephalitis in patients of West Bengal, India, 2010. Virol J 9: 271 [CrossRef] [PubMed].
    [Google Scholar]
  49. Sarkar A., Banik A., Pathak B.K., Mukhopadhyay S.K., Chatterjee S.. ( 2013;). Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain. BMC Infect Dis 13: 368 [CrossRef] [PubMed].
    [Google Scholar]
  50. Schuh A.J., Ward M.J., Leigh Brown A.J., Barrett A.D.. ( 2013;). Phylogeography of Japanese encephalitis virus: genotype is associated with climate. PLoS Negl Trop Dis 7: e2411 [CrossRef] [PubMed].
    [Google Scholar]
  51. Schuh A.J., Ward M.J., Leigh Brown A.J., Barrett A.D.. ( 2014;). Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J Virol 88: 4522–4532 [CrossRef] [PubMed].
    [Google Scholar]
  52. Shrestha B., Brien J.D., Sukupolvi-Petty S., Austin S.K., Edeling M.A., Kim T., O'Brien K.M., Nelson C.A., Johnson S., other authors. ( 2010;). The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823 [CrossRef] [PubMed].
    [Google Scholar]
  53. Sjatha F., Kuwahara M., Sudiro T.M., Kameoka M., Konishi E.. ( 2014;). Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response. Microbiol Immunol 58: 126–134 [CrossRef] [PubMed].
    [Google Scholar]
  54. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., Khanh V.T.. ( 2000;). Japanese encephalitis. J Neurol Neurosurg Psychiatry 68: 405–415 [CrossRef] [PubMed].
    [Google Scholar]
  55. Solomon T., Ni H., Beasley D.W.C., Ekkelenkamp M., Cardosa M.J., Barrett A.D.T.. ( 2003;). Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 77: 3091–3098 [CrossRef] [PubMed].
    [Google Scholar]
  56. Sukupolvi-Petty S., Brien J.D., Austin S.K., Shrestha B., Swayne S., Kahle K., Doranz B.J., Johnson S., Pierson T.C., other authors. ( 2013;). Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 87: 8826–8842 [CrossRef] [PubMed].
    [Google Scholar]
  57. Teoh E.P., Kukkaro P., Teo E.W., Lim A.P., Tan T.T., Yip A., Schul W., Aung M., Kostyuchenko V.A., other authors. ( 2012;). The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4: 139ra83 [CrossRef] [PubMed].
    [Google Scholar]
  58. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., Lanzavecchia A.. ( 2004;). An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871–875 [CrossRef] [PubMed].
    [Google Scholar]
  59. Tsai T.F., Yong-Xin Y., Li J.L., Putvatana R., Ran Z., Shougui W., Halstead S.B.. ( 1998;). Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine – a comparison of 1- and 3-month immunization schedules. J Infect Dis 177: 221–223 [CrossRef] [PubMed].
    [Google Scholar]
  60. Uchil P.D., Satchidanandam V.. ( 2001;). Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg 65: 242–251 [PubMed].
    [Google Scholar]
  61. van den Hurk A.F., Ritchie S.A., Mackenzie J.S.. ( 2009;). Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54: 17–35 [CrossRef] [PubMed].
    [Google Scholar]
  62. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M.. ( 2010;). Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6: e1000821 [CrossRef] [PubMed].
    [Google Scholar]
  63. Wills M.R., Singh B.K., Debnath N.C., Barrett A.D.. ( 1993;). Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses. Vaccine 11: 761–766 [CrossRef] [PubMed].
    [Google Scholar]
  64. Wong S.S., Abd-Jamil J., Abubakar S.. ( 2007;). Antibody neutralization and viral virulence in recurring dengue virus type 2 outbreaks. Viral Immunol 20: 359–368 [CrossRef] [PubMed].
    [Google Scholar]
  65. Wu S.C., Lian W.C., Hsu L.C., Liau M.Y.. ( 1997;). Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 51: 173–181 [CrossRef] [PubMed].
    [Google Scholar]
  66. Wu K.P., Wu C.W., Tsao Y.P., Kuo T.W., Lou Y.C., Lin C.W., Wu S.C., Cheng J.W.. ( 2003;). Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem 278: 46007–46013 [CrossRef] [PubMed].
    [Google Scholar]
  67. Ye Q., Li X.F., Zhao H., Li S.H., Deng Y.Q., Cao R.Y., Song K.Y., Wang H.J., Hua R.H., other authors. ( 2012;). A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1′ formation and contributes to attenuation. J Gen Virol 93: 1959–1964 [CrossRef] [PubMed].
    [Google Scholar]
  68. Ye Q., Li X.F., Zhao H., Deng Y.Q., Xu Y.P., Wang H.Y., Liang G.D., Qin C.F.. ( 2014;). Reduction of neutralization antibody against heterologous circulating strains in adults immunized with Japanese encephalitis live vaccine. Hum Vaccin Immunother 10: 2704–2705 [CrossRef] [PubMed].
    [Google Scholar]
  69. Yu Y.. ( 2010;). Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28: 3635–3641 [CrossRef] [PubMed].
    [Google Scholar]
  70. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J.H., Baker T.S., Kuhn R.J., Rossmann M.G.. ( 2004;). Conformational changes of the flavivirus E glycoprotein. Structure 12: 1607–1618 [CrossRef] [PubMed].
    [Google Scholar]
  71. Zhang J.S., Zhao Q.M., Guo X.F., Zuo S.Q., Cheng J.X., Jia N., Wu C., Dai P.F., Zhao J.Y.. ( 2011;). Isolation and genetic characteristics of human genotype 1 Japanese encephalitis virus, China, 2009. PLoS One 6: e16418 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000160
Loading
/content/journal/jgv/10.1099/vir.0.000160
Loading

Data & Media loading...

Supplements

Supplementary Data



PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error